"id:ID","studyTitle","studyRationale","uuid","studyVersion","id","studyAcronym"
"821","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","8e5b466f-eec7-4619-ba28-cd23f1a89292","2","StudyVersion_1","H2Q-MC-LZZT"
